Literature DB >> 8008226

The economic cost of migraine. Present state of knowledge.

G de Lissovoy1, S S Lazarus.   

Abstract

The costs of medical care and lost productivity associated with migraine headache impose an economic burden on society. Knowledge of the costs that can be attributed to migraine would provide a basis for evaluating alternative diagnosis and treatment strategies. The most widely used approaches to analyzing the cost of illness analysis are the willingness-to-pay and human capital methods. Using these as a framework, all recent published studies (from 1980 to the present) relevant to the economic cost of migraine were reviewed. The literature reviewed demonstrates that the economic burden of migraine headache is substantial. To estimate the cost of migraine to society more precisely, data are needed on incidence and prevalence among carefully selected samples representative of the underlying population. Use of medical care must be expressed as units of specific types of services rendered over known periods. Health insurance coverage, an important determinant of access to care, should also be known. Absenteeism and work losses must be linked to occupation and earnings levels.

Entities:  

Mesh:

Year:  1994        PMID: 8008226

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

Review 1.  Cost-of-illness studies. Useful for health policy?

Authors:  M A Koopmanschap
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

2.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 3.  A review of health-related workplace productivity loss instruments.

Authors:  Jennifer H Lofland; Laura Pizzi; Kevin D Frick
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Workplace productivity. A review of the impact of migraine and its treatment.

Authors:  P Stang; R Cady; A Batenhorst; L Hoffman
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 5.  Sumatriptan. A pharmacoeconomic review of its use in migraine.

Authors:  A J Coukell; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

6.  A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity.

Authors:  P Cortelli; C Dahlöf; J Bouchard; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

7.  A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life.

Authors:  C Dahlöf; J Bouchard; P Cortelli; J Heywood; J P Jansen; S Pham; J Hirsch; J Adams; D W Miller
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

8.  A multinational investigation of the impact of subcutaneous sumatriptan. I: Design, methods and clinical findings.

Authors:  J Heywood; J Bouchard; P Cortelli; C Dahlöf; J P Jansen; S Pham; J Hirsch; C E Edwards; J Adams; P Berto; B Brueggenjuergen; A L Nyth; P Lindsay; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

Review 9.  Burden of migraine. A review of its socioeconomic impact.

Authors:  G D Solomon; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

Review 10.  The burden of migraine. A review of cost to society.

Authors:  R B Lipton; W F Stewart; M Von Korff
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.